Minerva Neurosciences | NERV - Interest Expense On Debt


Minerva Neurosciences reported $2.31M in Interest Expense on Debt for its fiscal quarter ending in June of 2024.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Adma Biologics USD 2.1M 474K Mar/2026
ALKERMES USD 25.92M 5.03M Jun/2026
AstraZeneca USD 340M 144M Jun/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
Bristol-Myers Squibb USD 407M 4M Jun/2026
Cipla INR 170.3M 39M Jun/2026
Compugen USD 1.35M 399K Mar/2026
CSL USD 215M 111M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
GlaxoSmithKline GBP 121M 46M Jun/2026
Grifols EUR 156.07M 31.46M Sep/2025
Halozyme Therapeutics USD 5.59M 80K Jun/2026
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
J&J USD 43M 25M Mar/2026
Merck USD 525M 46M Jun/2026
Minerva Neurosciences USD 2.31M 60K Jun/2024
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 462M 119M Jun/2026
Novavax USD 5.82M 342K Dec/2025
Pfizer USD 667M 4M Jun/2026
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR 287M 109M Jun/2026
Takeda JPY 63.85B 20.2B Jun/2026
Vanda Pharmaceuticals -1.37B 1.97B Dec/2025